CFV: sci.med.diseases.als

David Bostwick david.bostwick at chemistry.gatech.edu
Mon Jan 15 19:59:32 EST 1996


                     FIRST CALL FOR VOTES (of 2)
                unmoderated group sci.med.diseases.als

Newsgroups line:
sci.med.diseases.als	Amyotrphic Lateral Sclerosis research and care.

Votes must be received by 23:59:59 UTC, 5 Feb 1996.

This vote is being conducted by a neutral third party.  Questions about
the voting process should be directed to the votetaker.  Questions about
the proposed group should be directed to the proponent.

Proponent: Jan Rodman <alssoc at inforamp.net>
Votetaker: David Bostwick <david.bostwick at chemistry.gatech.edu>

RATIONALE: sci.med.diseases.als

There is currently no usenet discussion group for the many persons
interested in studying or affected by amyotrophic lateral sclerosis,
more commonly known as ALS.  In North America, it is also called Lou
Gehrig's Disease.  In South America, Europe, Australia and Asia, ALS
is included in the group of neuromuscular diseases commonly known as
MND (Motor Neurone Disease).

Amyotrophic lateral sclerosis is a rapidly progressive, neuromuscular
disease.  It attacks the motor neurons responsible for transmitting
electrical impulses from the brain to the voluntary muscles throughout
the body.  When these muscles fail to receive messages, they
eventually lose strength, atrophy and die.  There is no known
treatment or cure.  Except in some rare instances when an apparent
prolonged remission seems to have occurred, ALS is at present
generally accepted as a fatal disease.

ALS cannot be *caught* -- it is not contagious.  In 90% of ALS cases,
it strikes people with no family history of the disease.  10% are
classified as familial or inherited ALS.  It may occur at any age,
with the likelihood increasing as people grow older.  ALS occurs
equally in men and women.

Because the disease frequently takes its toll before being positively
diagnosed, many patients are debilitated before learning they have
contracted ALS.  The disease does not affect the senses -- taste,
touch, sight, smell and hearing -- or the mind.  Education of
healthcare professionals as to the nature of the disease is a
priority.

ALS wreaks a devastating effect on patients as well as their families.
As they struggle to cope with the prospect of advancing disability and
death, it consumes their financial and emotional reserves.  It is a
costly disease in its later stages, demanding both extensive nursing
care and expensive equipment.  The target population therefore
includes not only researchers, but also people with ALS, their
families, caregivers and healthcare providers.

This proposed newsgroup would enable researchers and doctors from all
over the medical and scientific community who are studying this
disease to communicate via the ALS newsgroup, and could be invaluable
help in the development of new concepts and ideas and in the
dissemination of useful information to all persons concerned with ALS.
The newsgroup would also give patients a forum to discuss the disease,
and offer support.

CHARTER: sci.med.diseases.als

The proposed newsgroup, sci.med.diseases.als is intended for
discussion about the many different aspects of ALS, its symptoms,
latest treatment options, research concepts and ideas, as well as how
ALS is experienced by patients, their caregivers, friends and family
members, doctors and other medical professionals, or anyone affected
by or involved with ALS.

Anyone with an interest in ALS is free to post, in addition to the
medical and scientific community.  This newsgroup is interested both
in providing an open forum for the exchange of medical and scientific
information, which can be useful to all participants, and in fostering
communication between people affected by ALS from all parts of the
globe.  Above all, we wish to encourage a supportive and open
atmosphere for the free exchange of opinions and information.

The following are examples of possible posting topics:

ALS research concepts, ideas and findings
new information and resources available about the disease
questions regarding any aspect of ALS
symptoms and problems arising from the onset of new symptoms
treatments and therapies, both conventional and alternative
problems in the medical community in regard to ALS
emotions, including fears and anxieties caused by this illness
social issues regarding this illness
related practical problems or solutions

Commercial advertisements may NOT be posted to this proposed group.

END CHARTER.

HOW TO VOTE

Delete everything above the top "-=-=-" line and delete everything
below the bottom -=-=-" line.  Do not change anything between these
lines, except to add your name and vote.

Give your name on the line that asks for it.  For each group, put your
vote in the brackets next to the group name.  Valid entries are
ABSTAIN, CANCEL, NO, and YES.  Anything else may generate an invalid
vote.  Don't worry about changes in spacing or any quote characters
(">") that your reply may insert.

Mail the ballot to <david.bostwick at chemistry.gatech.edu>.  Just
replying to this should work, but check the "To:" line.  Votes must be
mailed directly from the voter to the votetaker.  Distributing
pre-marked or otherwise edited ballots is considered vote fraud.

Only one vote is allowed per person or per account.  Votes will be
acknowleged by e-mail.  If you have not received an acknowledgement
within a few days, contact the votetaker.  It is your responsibility
to be certain your vote has been recorded correctly.  If you want to
change your vote, you may vote again, but only the latest vote will be
counted.  Addresses and votes of all voters will be published in the
final vote ack.

The purpose of a Usenet vote is to determine the genuine interest of
people who would read a proposed newsgroup.  Soliciting votes from
disinterested parties defeats this purpose.  Please do not distribute
this CFV.  If you must, direct people to the official CFV as posted in
news.groups.  When in doubt, ask the votetaker.

-=-=- BEGINNING OF BALLOT: DELETE EVERYTHING ABOVE THIS LINE =-=-=-=-=-=-=
This ballot is available only from postings  |   FIRST CALL FOR VOTES    |
in news.groups or by e-mail from the         |   SCI.MED.DISEASES.ALS    |
votetaker.  It is distributed blank.  Votes  |         <SMDA-0001>       |
are counted by computer, and failure to use  =============================
this ballot increases the possibility that the software will be unable to
process your vote properly.  Do not edit this ballot except to add your
name and indicate your vote.

These are examples of how to mark the ballot.  Do not vote here.
[   YES   ] example.yes.vote
[   NO    ] example.no.vote
[ ABSTAIN ] example.abstain.vote
[ CANCEL  ] example.cancel.vote

The placement of the word within the brackets is not important, but use the
complete word, not just one letter.

Enter your name and indicate your vote in the spaces below.
------------------------------------------------------------------------

Give your real name here:
If you do not give your real name, your vote may be rejected.

[Your Vote]  Group (Place your vote in the brackets next to the group)
-------------------------------------------------------------------------
[         ]  sci.med.diseases.als
-=-=-=-=  END OF BALLOT: DELETE EVERYTHING BELOW THIS LINE  =-=-=-=-=-=-=



More information about the Bionews mailing list